What factors impact your choice of first line therapy for PDL1-negative metastatic TNBC?

The first-line treatment landscape for PD-L1-negative metastatic TNBC has been transformed by ASCENT-03 and TROPION-Breast02. ASCENT-03 showed improved median PFS with sacituzumab govitecan compared with chemotherapy, while TROPION-Breast02 showed improved PFS with datopotamab deruxtecan and also de...

For patients with advanced triple-negative breast cancer (TNBC) with a PD-L1 combined positive score (CPS) less than 10, first-line treatment options include the antibody-drug conjugates (ADCs) sacituzumab govitecan (SG), as supported by ASCENT-03 [1], or datopotamab deruxtecan (Dato-DXd), as suppor...

We are fortunate that we have two ADC choices. I think these decisions are made based on (1) familiarity with ADC and its AEs; (2) the AE profile; and (3) dosing interval. I think the efficacy of both SG and Dato-DXd is roughly equivalent. It is likely to involve preferences of the patient and the p...

We are fortunate to have two ADCs that have proven superiority to chemotherapy in the first-line setting for patients who are not candidates for checkpoint inhibitors. Both DatoDxd and SG are category 1 preferred options according to NCCN for this setting and are favored over chemotherapy. Aside fro...